Biomarker Identification through Proteomics in Colorectal Cancer.
Desirรฉe Martรญn-Garcรญa, Marilina Garcรญa-Aranda, Maximino Redondo
https://pubmed.ncbi.nlm.nih.gov/38396959Actively Recruiting
Led by Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis ยท Updated on 2025-12-19
60
Participants Needed
1
Research Sites
52 weeks
Total Duration
A
Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Lead Sponsor
U
University of Bari Aldo Moro
Collaborating Sponsor
Researchers are conducting an observational study to find new non-invasive biomarkers in the blood of patients with colorectal cancer (CRC). The goal is to develop a score that can predict the development of CRC. The study includes three groups: patients diagnosed with CRC undergoing surgery, individuals with a negative colonoscopy result, and those with adenoma with high-grade dysplasia, a precancerous condition. Participants in the first group will have their medical and family history reviewed and provide blood samples before and after surgery. Tissue samples leftover from surgery will also be collected for molecular analysis. Those in the second and third groups will undergo history reviews and blood sample collection after their colonoscopy, with enrollment based on their diagnosis. Blood samples will be analyzed for known tumor markers and potential new biomarkers using specialized lab techniques, including ATR-FTIR spectroscopy and protein characterization from extracellular vesicles. Participants will be assessed through medical history reviews, blood tests, and tissue analysis. Researchers will measure changes in serum biomarkers and the composition of biological samples from enrollment until about 20 days later. The study also involves storing samples in a biobank for further analysis. Safety monitoring and long-term follow-up are not detailed, but participants will be engaged mainly through these diagnostic and laboratory procedures during the study period.
CONDITIONS
Identification of New Non-invasive, Predictive, and Diagnostic Biomarkers for Colorectal Cancer
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to enrollment day
Participants undergo diagnostic procedures such as colonoscopy or surgery as part of normal clinical practice, and relevant clinical history and blood samples are collected.
1 visit (in-person) for history review and blood sample collection
Duration - Approximately 20 days
Participants are observed with blood samples collected at enrollment and again about 20 days later to measure biomarkers related to colorectal cancer.
2 visits (in-person): one at enrollment and one follow-up visit about 20 days later
Total: 1 location
1
Biobank Core Facility
Castellana Grotte, Italy, 70013
Actively Recruiting
P
Pasqua Letizia Pesole, Biologist
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Desirรฉe Martรญn-Garcรญa, Marilina Garcรญa-Aranda, Maximino Redondo
https://pubmed.ncbi.nlm.nih.gov/38396959Shailja C Shah, Steven H Itzkowitz
https://pubmed.ncbi.nlm.nih.gov/34757143Jared A Sninsky, Brandon M Shore, Gabriel V Lupu...
https://pubmed.ncbi.nlm.nih.gov/35361331